{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"286"},{"groupId":"OG001","value":"242"}]}],"title":"Patients With Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"656"},{"groupId":"OG001","value":"702"}]}],"title":"Patients Without Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"942"},{"groupId":"OG001","value":"944"}],"units":"Participants"}],"description":"Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.","groups":[{"description":"Given by one of two regimens. • Mayo Clinic regimen group: LV 20 mg/m\\^2 IV bolus injection + 5-FU 425 mg/m\\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or • Roswell Park regimen group: LV 500 mg/m\\^2 by two-hour IV infusion + 5-FU 500 mg/m\\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks)","id":"OG000","title":"5-FU/LV"},{"description":"Capecitabine administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks)","id":"OG001","title":"XELOX"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants who gave written informed consent. Participants in the ITT population were analyzed according to the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months).","title":"Overall Survival [Number of Events]","type":"SECONDARY","unitOfMeasure":"Participants"}